Leader Biomedical Group receives approval to distribute bioresorbable grafts in Switzerland
European Medical Contract Manufacturing BV, a Leader Biomedical Group company, has received regulatory approval from Swissmedic to place its range of eTiss® human allografts for dental and orthopaedic applications on the Swiss market.
Using its proprietary eCOO® Technology, Leader Biomedical is able to produce a range of bioresorbable grafts for the Orthopaedic and Dental markets. The eCOO® Technology platform is a milder alternative to cleaning, sterilising, and impregnating human and animal derived bone and tissue using supercritical carbon dioxide (scCO2) instead of harsh chemicals. Grafts processed with eCOO® Technology exhibit certain bio-molecular and mechanical characteristics, such as slower protein degradation, better cell adhesion, superior tensile strength and torque, which make it ideal for indications requiring a graft with weight bearing and tension-sensitive requirements.
The registration was filed at the request of one of its dental customers, a Swiss company active in regenerative care.